TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Profusa ( (PFSA) ) has provided an update.
On August 6, 2025, Profusa, Inc. announced significant milestones, including its recent public listing on Nasdaq and strategic plans for growth. The company outlined a five-pillar strategy focusing on revenue growth, AI infrastructure, clinical pathways, financial strategies, and scaling operations. Profusa is advancing its Lumee™ platform for tissue oxygen monitoring, targeting a European launch in Q1 2026, and plans to expand into the U.S. market by 2027. The company also aims to commercialize its glucose monitoring platform by mid-2027, supported by a $100 million ELOC facility to ensure financial stability.
More about Profusa
Profusa, based in Berkeley, California, is a commercial stage digital health company focused on developing tissue-integrated sensors for continuous monitoring of biochemistry. The company aims to provide personalized biochemical data for personal and medical use through its injectable biosensors and intelligent data platform.
Average Trading Volume: 7,375,546
Technical Sentiment Signal: Sell
Current Market Cap: $17.36M
Learn more about PFSA stock on TipRanks’ Stock Analysis page.